<DOC>
	<DOCNO>NCT02292745</DOCNO>
	<brief_summary>The purpose study investigate whether combine FOLFIRINOX chemotherapy stereotactic radiotherapy patient locally advanced pancreatic cancer lead increase survival .</brief_summary>
	<brief_title>Efficacy Feasibility Combining FOLFIRINOX Stereotactic Radiotherapy Patients With Irresectable Locally Advanced Pancreatic Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Cytological histologically confirmation pancreatic cancer . WHO performance status 0 1 ASA classification I II Tumor consider locally advanced diagnostic workup include CTimaging diagnostic laparoscopy . No evidence metastatic disease Largest tumor diameter &lt; 7 cm x 7 cm x 7 cm Normal renal function ( Creatinine â‰¥ 30 ml/min ) . Normal liver test ( bilirubin &lt; 1.5 time normal ; ALAT/ASAT &lt; 5 time normal ) Normal bone marrow function ( WBC &gt; 3.0 x 10e9/L , platelet &gt; 100 x 10e9/L hemoglobin &gt; 5.6 mmol/l ) Age &gt; 18 year &lt; 75 year Written inform consent Prior radiotherapy , chemotherapy resection ( bypass surgery allow ) . Lymph node metastasis primary tumor outside field radiation . Second primary malignancy except situ carcinoma cervix , adequately treat nonmelanoma skin cancer , malignancy treat least 3 year previously without evidence recurrence . Pregnancy , breast feeding . Serious concomitant systemic disorder would compromise safety patient his/her ability complete study , discretion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>locally advanced pancreatic cancer</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>stereotactic radiotherapy</keyword>
</DOC>